This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Rivastigmine in the treatment of dementia associated with Parkinson’s disease: effects on activities of daily living

Authors

Olin, Jason T., Aarsland, Dag, Meng, Xiangyi

Journal

Dementia And Geriatric Cognitive Disorders, Volume: 29, No.: 6, Pages.: 510-515

Year of Publication

2010

Abstract

Aims: To investigate the effects of rivastigmine capsule 3-12 mg/day over 24 weeks on activities of daily living (ADLs) in patients with dementia associated with Parkinson’s disease (PDD).; Methods: Post hocanalysis of a prospective, multicenter, randomized, double-blind, placebo-controlled trial in patients with PDD (>or=50 years) randomized to rivastigmine 3-12 mg/day (capsules bid) or placebo over 24 weeks. This analysis was carried out with three subscales derived from a factor analysis of the 23 items in the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) scale. These subscales were basic ADLs (10 items), high-level function ADLs (eight items) and autonomy ADLs (five items).; Results: 541 patients were randomized (362 to rivastigmine, 179 to placebo) and 410 (75.8%) completed the study. Rivastigmine was associated with significantly better outcomes in basic ADLs (-0.5 +/- 6.19 vs. -1.7 +/- 5.46; p = 0.025; effect size 22.1%) and high-level function ADLs (0.1 +/- 4.95 vs. -1.0 +/- 4.49; p = 0.017; effect size 22.9%) compared with placebo, at week 24.; Conclusion: In patients with PDD, treatment with rivastigmine may show beneficial effects on overall ADLs, as well as modest, statistically significant improvements in basic ADLs and high-level function ADLs.; Copyright 2010 S. Karger AG, Basel.

Bibtex Citation

@article{Olin_2010, doi = {10.1159/000305100}, url = {http://dx.doi.org/10.1159/000305100}, year = 2010, publisher = {S. Karger {AG}}, volume = {29}, number = {6}, pages = {510--515}, author = {Jason T. Olin and Dag Aarsland and Xiangyi Meng}, title = {Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: Effects on Activities of Daily Living}, journal = {Dementia and Geriatric Cognitive Disorders} }

Keywords

activities of daily living, aged, aged, 80 and over, cholinesterase inhibitors, classification, complications, dementia, double-blind method, drug therapy, etiology, female, humans, male, middle aged, parkinson disease, phenylcarbamates, rivastigmine, therapeutic use, treatment outcome

Countries of Study

USA

Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime